These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 32780250)

  • 1. The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib.
    Patel AA; Odenike O
    Curr Hematol Malig Rep; 2020 Dec; 15(6):409-418. PubMed ID: 32780250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis.
    Talpaz M; Kiladjian JJ
    Leukemia; 2021 Jan; 35(1):1-17. PubMed ID: 32647323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis.
    Sureau L; Orvain C; Ianotto JC; Ugo V; Kiladjian JJ; Luque Paz D; Riou J
    Blood Cancer J; 2021 Jul; 11(7):135. PubMed ID: 34315858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of myelofibrosis after ruxolitinib failure.
    Harrison CN; Schaap N; Mesa RA
    Ann Hematol; 2020 Jun; 99(6):1177-1191. PubMed ID: 32198525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN).
    Isfort S; von Bubnoff N; Al-Ali HK; Becker H; Götze T; le Coutre P; Griesshammer M; Moskwa C; Wohn L; Riedel J; Palandri F; Manz K; Hochhaus A; Döhner K; Heidel FH
    Ann Hematol; 2024 Aug; 103(8):2775-2785. PubMed ID: 38967662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2.
    Harrison CN; Vannucchi AM; Recher C; Passamonti F; Gerds AT; Hernandez-Boluda JC; Yacoub A; Sirhan S; Ellis C; Patel B; Strouse B; Platzbecker U
    Adv Ther; 2024 Sep; 41(9):3722-3735. PubMed ID: 38990433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures.
    Singer JW; Al-Fayoumi S; Taylor J; Velichko S; O'Mahony A
    PLoS One; 2019; 14(9):e0222944. PubMed ID: 31560729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium.
    Griesshammer M; Sadjadian P
    Expert Opin Pharmacother; 2017 Dec; 18(18):1929-1938. PubMed ID: 29134817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy for myeloproliferative neoplasms: when, which agent, and how?
    Geyer HL; Mesa RA
    Blood; 2014 Dec; 124(24):3529-37. PubMed ID: 25472969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An evaluation of fedratinib for adult patients with newly diagnosed and previously treated myelofibrosis.
    Saleh K; Ribrag V
    Expert Rev Hematol; 2023 Apr; 16(4):227-236. PubMed ID: 36939633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent progress of JAK inhibitors for hematological disorders.
    Kirito K
    Immunol Med; 2023 Sep; 46(3):131-142. PubMed ID: 36305377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [JAK inhibitors for myelofibrosis: ruxolitinib and momelotinib].
    Kosugi H
    Rinsho Ketsueki; 2024; 65(8):798-809. PubMed ID: 39231711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances with janus kinase inhibitors for the treatment of myeloproliferative neoplasms: an update of the literature.
    Hunter AM; Bose P
    Expert Opin Pharmacother; 2024 Jul; 25(10):1391-1404. PubMed ID: 39067001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel therapeutics in myeloproliferative neoplasms.
    Venugopal S; Mascarenhas J
    J Hematol Oncol; 2020 Dec; 13(1):162. PubMed ID: 33267911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Momelotinib in myelofibrosis.
    Bruzzese A; Martino EA; Labanca C; Mendicino F; Lucia E; Olivito V; Zimbo A; Fragliasso V; Neri A; Morabito F; Vigna E; Gentile M
    Expert Opin Pharmacother; 2024 Apr; 25(5):521-528. PubMed ID: 38623844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
    Mascarenhas J; Hoffman R; Talpaz M; Gerds AT; Stein B; Gupta V; Szoke A; Drummond M; Pristupa A; Granston T; Daly R; Al-Fayoumi S; Callahan JA; Singer JW; Gotlib J; Jamieson C; Harrison C; Mesa R; Verstovsek S
    JAMA Oncol; 2018 May; 4(5):652-659. PubMed ID: 29522138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacotherapeutic advances for splenomegaly in myelofibrosis.
    Tremblay D; Mascarenhas J
    Expert Opin Pharmacother; 2023 Apr; 24(5):577-585. PubMed ID: 36922391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [What's new in myeloproliferative neoplasia?].
    Schmidt S; Wolf D
    Dtsch Med Wochenschr; 2022 Mar; 147(6):306-311. PubMed ID: 35291035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis.
    Tefferi A; Pardanani A; Gangat N
    Haematologica; 2023 Nov; 108(11):2919-2932. PubMed ID: 36861402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety considerations when treating myelofibrosis.
    O'Sullivan JM; McLornan DP; Harrison CN
    Expert Opin Drug Saf; 2016 Sep; 15(9):1185-92. PubMed ID: 27187785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.